The present invention relates to N-(3,5-dichloropyridin4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide in crystalline form having crystalline modification II as defined in the claims. The invention also relates to a method for manufacturing the modification II, a pharmaceutical composition comprising said modification II and said modification II for use as a medicament.
本发明涉及晶体形式为II型的N-(3,5-二
氯吡啶-4-基)-[1-(4-
氟苯基甲基)-
7-氮杂吲哚-3-基]甘
氨酸酰胺。该发明还涉及制备II型晶体形式的方法,包括所述II型晶体形式和所述II型晶体形式作为药物的制药组合物。